The nation of Zimbabwe has rejected a major American healthcare agreement valued at $367m (£272m) over five years over Washington's insistence on confidential biological samples.
This move was revealed after a official document from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
A government representative has since clarified that the US was requesting biological samples for research and commercial gain but was not willing to share the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for further dialogue to find a agreement agreeable to both sides so the country's critical HIV treatment initiative can continue.
Wider Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the security of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump stated its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost transparency and responsibility.
Based on reports, Sixteen nations in Africa have so far signed these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, without any equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our nation would supply the basic resources for scientific discovery with no assurance that the end products would be accessible to our people should a new health crisis arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one deals were undermining structures already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This framework is intended to guarantee that when a country contributes its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage ongoing discussions with our US partners on how future collaboration could be arranged in a manner that honours the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that talks need to persist given that a large portion of the country's HIV programmes relied on foreign aid.
"In cases where technical issues arise, such as those relating to data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," it commented.
The situation highlights the ongoing challenges between accepting crucial international aid and safeguarding national sovereignty in an increasingly data-driven world.